CVS (CVS) has appointed four new members to its board as part of a deal with activist investor Glenview Capital. Glenview’s CEO will join the board along with three other directors, bringing the total number of board members to 16.

Catalysts Co-hosts Brad Smith and Madison Mills break down the move, which follows Glenview’s $700 million stake in CVS and its push to improve the company’s performance, after shares have dropped more than 30% year-to-date.

To watch more expert insights and analysis on the latest market action, check out more Catalysts here.

This post was written by Cindy Mizaku.